[pending] EPTIFIBATIDE (EPTIFIBATIDE)
Pending LLM rewrite. Source: FDA_DRUG D-0343-2026.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: Pending LLM scoring against the rubric.
Plain-English summary
Labeling: Not Elsewhere Classified. The carton for Eptifibatide Injection 75 mg/100 mL states 75 mg/100 mL vial for weight-adjusted bolus dosing. The approved statement is 75 mg/100 mL vial for weight-adjusted infusion.
The recalled product
- Product
- EPTIFIBATIDE (EPTIFIBATIDE)
- Brand
- EPTIFIBATIDE
- Manufacturer
- Slate Run Pharmaceuticals
- Category
- Drug — Drugs
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lots within expiry
UPCs (2)
- 0370436027804
- 0370436163809
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · EPTIFIBATIDE
- ModerateDrug Recall: Eptifibatide Injection Due to Failed Degradation Specifications
FDA (Drugs) · 2024-06-26
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- ModeratePrimidone Tablets Recalled Due to API Cross-Contamination
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- SevereErythromycin Tablets Recalled for Impurity Above Acceptable Limits
FDA (Drugs) · 2026-05-27